Gimatecan (ST1481) is a potent topoisomerase I inhibitor. Gimatecan is an orally bioavailable camptothecin analogue with antitumor activity[1].
Biological Activity
Gimatecan (ST1481) is a potent topoisomerase I inhibitor. It is an orally active camptothecin analog with antineoplastic activity.
in vivo
Gimatecan (2 mg/kg; treatment per os, every fourth day for four times) is effective for inhibiting tumor growth.
< div class="cpd-mod-vv">
Animal Model:
Athymic Swiss nude mice bearing HT1376 model
Dosage:
2 mg/kg
Administration:
Treatment per os, every fourth day for four times
Result:
Caused a marked tumor growth inhibition during treatment.
table>
target
Topoisomerase I
IC 50
Topoisomerase I
References
[1] Paola Ulivi, et al. Cellular Basis of Antiproliferative and Antitumor Activity of the Novel Camptothecin Derivative, Gimatecan, in Bladder Carcinoma Models. Neoplasia. 2005 Feb;7(2):152-61. DOI:10.1593/neo.04397
